Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes

Diabetic Medicine

Volumn 26, Issue 11, 2009, Pages 1156-1164

  Kapitza, C ^a   Heise, T ^b   Birman, P ^c   Jallet, K ^c   Ramis, J ^c   Balena, R ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Profil Institut fur Stoffwechselforschung GmbH   (Germany)

^c IPSEN   (France)

Author keywords

Glucagon like peptide 1 analogue; Pharmacodynamics; Pharmacokinetics; Safety; Taspoglutide

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; METFORMIN; PLACEBO; TASPOGLUTIDE; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERUCTATION; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INJECTION SITE REACTION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UPPER ABDOMINAL PAIN; VOMITING;

DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME;

EID: 70350764845     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02854.x     Document Type: Article

References (18)

1. International Diabetes Federation. Diabetes facts and figures. Available at http://www.idf.org/home Last accessed 15 April 2008.
2. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007 30 : S4 S41.
3. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 28 : 88 136.
4. 1c targets. A guidance statement from the American College of Physicians. Ann Intern Med 2007 147 : 417 422.
5. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes: recommendations for standard, comprehensive and minimal care. Diabet Med 2006 23 : 579 593.
6. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006 29 : 531 537.
7. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007 298 : 194 206. (Pubitemid 47057766)
8. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999 281 : 2005 2012.
9. Deacon CF. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2007 9 : 23 31.
10. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 32 : 193 203.
11. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes. Part II: incretin-based therapy and beyond. Circulation 2008 117 : 574 584.
12. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 368 : 1696 1705.
13. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999 48 : 2270 2276.
14. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003 278 : 471 478.
15. Riddle MC. Measuring fructosamine at home. Diabetes Technol Ther 2000 2 : 239 240.
16. Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009 32 : 1237 1243.
17. Edwards C, Winocour PH. ABCD position statement on incretin mimetics and DPP-4 inhibitors - 2009. Pract Diab Int 2009 26 : 191 194.
18. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007 30 : 1487 1493.